Steven Edelman, MD and Robert Henry, MD explain the clinical characteristics that would lead to the use of a DPP-4 inhibitor versus a GLP-1 receptor agonist. They discuss the drugs’ different effects on weight and how patients’ duration of diabetes play a role in determining which drug will be most effective. The use of a GLP-1 receptor agonist in combination with basal insulin is another therapeutic approach that is discussed.